Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in Kuwait.
Campus
Campus

The InRange Study

In the InRange study, glucose variability with second-generation basal insulin analogs Glargine 300 U/ml and Degludec 100 U/ml was evaluated by continuous glucose monitoring in people with T1DM. Join us as Prof. Rich Bergenstal, endocrinologist and executive director of the International Diabetes Centre at Health Partners in Minneapolis, presents the InRange study's design and findings.

Related articles
Advancing Therapy with iGlarLixi: Differentiation from other complex regimens
  • Diabetes

Advancing Therapy with iGlarLixi: Differentiation from other complex regimens

An educational video outlining key data from indirect comparisons of iGlarLixi versus IDegAsp.

Read article
Advancing Therapy with iGlarLixi: Differentiation from complex insulin regimens
  • Diabetes

Advancing Therapy with iGlarLixi: Differentiation from complex insulin regimens

An educational video outlining key data from indirect comparisons of iGlarLixi versus IDegAsp.

Read article
Insulin advancement in Type 2 diabetes: Unmet needs with commonly-used options
  • Diabetes

Insulin advancement in Type 2 diabetes: Unmet needs with commonly-used options

Educational video on "Insulin advancement in Type 2 diabetes: Unmet needs with commonly-used options" outlining key data from indirect comparisons of iGlarLixi versus IDegAsp.

Read article
MAT-BH-2400491/v1/Aug 2024